Reports

- Global Locations -

Headquarters

Future Market Insights, Inc.

Christiana Corporate, 200
Continental Drive, Suite 401,
Newark, Delaware - 19713,
United States

T: +1-347-918-3531

Americas

Future Market Insights, Inc.

616 Corporate Way, Suite 2-9018,
Valley Cottage, NY 10989, United States

MEA

Future Market Insights

1602-6 Jumeirah Bay X2 Tower, Plot No: JLT-PH2-X2A,
Jumeirah Lakes Towers, Dubai,
United Arab Emirates

Europe

Future Market Insights

3rd Floor, 207 Regent Street,
W1B 3HH London
United Kingdom

T: + 44 (0) 20 8123 9659

Asia Pacific

Future Market Insights

IndiaLand Global Tech Park, Unit UG-1, Behind Grand HighStreet, Phase 1, Hinjawadi, MH, Pune – 411057, India

Brain Tumor Treatment Market Snapshot (2023 to 2033)

The global brain tumor treatment market is expected to garner a market value of US$ 3,114.2 million in 2023 and is expected to accumulate a market value of US$ 6,228.2 million by 2033, registering a CAGR of 7.2% in the forecast period. The rising prevalence of such cancer and the growing geriatric population are key drivers expected to nurture the growth of the brain tumor diagnosis market worldwide. The market for brain tumor treatment registered a CAGR of 4.7% in the historical period.

Data Points Key Statistics
Brain Tumor Treatment Market Value 2023 US$ 3,114.2 million
Brain Tumor Treatment Market Projected Value (2033) US$ 6,228.2 million
Brain Tumor Treatment Market CAGR (2023 to 2033) 7.2%

A brain tumor is an abnormal and uncontrolled proliferation of cells in the brain. It can be benign or malignant. Brain tumor arises from brain tissue and rarely spreads. The tumor eventually compresses and damages other structures in the brain. According to American Brain Tumor Association (ABTA), there are two types of brain tumors - primary and secondary. Primary tumors arise from brain tissue and secondary tumors arise from other parts of the body and spread to the brain.

Gliomas are the most common type of primary tumor which arises from the brain’s glial tissue. Glioblastoma multiform is fast-growing and of a higher grade when compared to other tumors. Advanced medications are available to treat brain tumors. Increasing pharmaceutical Research and Development spending is expected to provide lucrative growth for the global brain tumor treatment industry over the forecasted period.

Based on region, North America is estimated to capture the highest share owing to the advanced healthcare facilities and hefty investment in the research program to find an effective treatment for brain tumors.

Don't pay for what you don't need

Customize your report by selecting specific countries or regions and save 30%!

Brain Tumor Treatment Demand Analysis (2018 to 2022) Vs Market Outlook (2023 to 2033)

The global demand for brain tumor treatment is projected to increase at a CAGR of 7.2% during the forecast period, reaching a total of US$ 6,228.2 million in 2033, according to a report from Future Market Insights (FMI). From 2018 to 2022, sales witnessed significant growth, registering a CAGR of 4.7%.

Over the years, accelerating research activities in the oncology sector and increasing adoption of advanced technologies for cancer treatment have augmented the demand for brain tumor therapeutics across the globe.

According to the Central Brain Tumor Registry of the USA (CBTRUS) statistical report of 2016, an estimated 79,270 new cases of primary malignant, non-malignant, and other CNS cancers were diagnosed in the United States in 2020 (26,070 primary malignant and 53,200 non-malignant). Thereby, the increasing prevalence of brain cancer cases across the globe is expected to propel the demand for brain tumor diagnosis/treatment throughout the forecast period.

Which Drivers underpin Brain Tumor Treatment Industry Expansion?

Growing on Chemotherapies and Increasing Awareness to Act as Principal Growth Drivers

An increase in the prevalence rate of brain tumors has fueled the demand for effective treatment. For instance, as per the American Society of Clinical Oncology (ASCO), the brain tumor incidence rate growing by 2.6% compared to the last year. An estimated 22,850 cases are diagnosed with primary cancerous tumors of the brain in the United States. Furthermore, the increasing geriatric population is also driving the brain tumor market.

As such, global companies are spending a significant portion of their revenue on Research and Development to develop novel medications. Numerous products related to novel drug delivery technologies are lined up for FDA approval. Increasing demand for advanced medication to treat brain tumors is expected to fuel the overall growth of the market. Increasing consumer awareness regarding the latest technological advancements in therapies, and medications are responsible for the growth of the global brain tumor treatment market.

Sabyasachi Ghosh
Sabyasachi Ghosh

Principal Consultant

Talk to Analyst

Find your sweet spots for generating winning opportunities in this market.

Which Factors are limiting the Growth of the Brain Tumor Treatment Market?

High Cost of Treatment May Hamper the Market Expansion of the Brain Tumor Treatment Market

Successfully treating brain tumors can be challenging. The body’s blood-brain barrier normally protects the brain and spinal cord from harmful chemicals. However, this barrier also keeps out many types of chemotherapy. Surgery can be difficult if the tumor is near a delicate part of the brain or spinal cord. Even when the surgeon can completely remove the original tumor, parts of the tumor may remain that are too small to be seen or removed during surgery. Radiation therapy can also damage healthy tissue.

However, research in the past 20 years has helped to significantly lengthen lives and improved the quality of life for many people with brain tumors. These advancements include more refined surgeries, a better understanding of which types of tumors respond to chemotherapy and other drugs, and more targeted delivery of radiation therapy. Besides, the higher initial cost of treatment and clinical trials may act as major roadblocks over the coming years.

Region-wise Insights

Is North America Projected to Hold a Significant Position in the Global Brain Tumor Treatment Market?

Advanced Healthcare Infrastructure & Presence of Innovative Research Centers Nurture the Demand for Brain Tumor Treatment

Region North America
Market Share % (2022) 34.2%

North America region is expected to dominate the global brain tumor treatment market throughout the forecast period, owing to increasing incidences of glioblastoma coupled with technological advancements. North America is expected to account for more than 34.2% share of the global brain tumor treatment market in 2023. Advanced healthcare infrastructure, greater per capita healthcare spending, and comparatively higher awareness regarding advanced technologies are certain to impact rendering factors.

Besides, the presence of advanced healthcare facilities and innovative research centers is another reason for fueling the demand for brain tumor treatment & therapeutics. For instance, the UCSF Brain Tumor Center is one of the largest and most comprehensive programs in the region for the treatment of brain and spinal tumors. This center includes advanced intra-operative imaging and brain mapping techniques to protect areas of the brain used for language, motor skills, and sensory function during surgery, as well as radiosurgery with Gamma Knife and CyberKnife and access to clinical trials of promising new therapies.

How is the Growth of the European Brain Tumor Treatment Market Projected to unfold?

Encouraging Healthcare Programs & Increasing Clinical Trials for Novel Drug Development to Spur Demand for Brain Tumor Treatment

Region Europe
Market Share % (2022) 24.2%

Europe is expected to contribute significantly to this space over the forecast period, which can be attributed to the increasing prevalence of malignant cancers in countries like the United Kingdom For instance, as per statistics provided by the Office for National Statistics, United Kingdom, in 2021, around 11,000 new cases were registered in the region.

Europe is the second largest in terms of market revenue and is estimated to witness significant gains throughout the forecast period. As per Future Market Insights, Europe is slated to account for a 21% share of the global brain tumor treatment market. This market growth is attributed to the increasing emphasis on cancer research and the rising prevalence of cancer cases in the region.

EANO is Europe’s multidisciplinary Neuro-Oncology organization representing all medical and scientific disciplines involved in the prevention, diagnosis, and treatment of tumors of the central nervous system (CNS). EANO is dedicated to promoting advances in Neuro-Oncology through innovative research and concerted education and training. Moreover, encouraging healthcare programs and the adoption of state-of-the-art technologies for the identification and treatment of malignant cancers in hospitals and healthcare facilities is likely to propel the brain tumor treatment market in the region.

How is the Asia Pacific Projected to Bolster the Demand for Brain Tumor Treatment?

Increasing Adoption of Cutting-edge Technology in Several Countries to Escalate the Market Growth of Brain Tumor Treatment

Country Market CAGR % (2023 to 2033)
China 8.8%
India 7.2%

The Asia Pacific represents a significant share of the brain tumor treatment market and is projected to experience robust growth throughout the forecast period, states Future Market Insights report. A significant increase in the incidence rate of brain tumors along with the shifting of locus of economic activity and dynamism to this region is expected to boost the demand for drugs responsible for brain tumor treatment.

The development of novel drugs and increasing clinical trials have boosted the market growth of the brain tumor treatment market in the Asia Pacific region. Encouraging healthcare policies and smooth drug approval programs by FDA are other aspects driving the market for brain tumor treatment.

Get the data you need at a Fraction of the cost

Personalize your report by choosing insights you need
and save 40%!

The Start-up Ecosystem How Key Players Are Opening Frontiers for Future Growth?

  • Founded in 2004, ViewRay is a developer of MRI-guided radiation therapy for the treatment of cancer. The company's MRI-enabled radiotherapy can be used to provide continuous soft-tissue imaging during treatment. The technology has potential applications in treating Lung, Breast, prostate, and Head/Neck cancers. The startup is based out of Oakwood (USA) and has raised overall funding of US$ 177 million to date.
  • Launched in 2009, RefleXion Medical is a Hayward (USA) based firm that developing a biology-guided radiotherapy (BgRT) system for targeted, personalized cancer treatment. Its patented technology leverages Positron Emission Tomography (PET) which allows tumors to continuously signal their location during treatment and guides personalized radiation therapy. The technology has applications in the treatment of lung, prostate, and breast cancers.

Competitive Landscape What are the Leading Players in the Brain Tumor Treatment Market up to?

  • In June 2022, Bristol Myers Squibb and Turning Point Therapeutics, Inc. announced a definitive merger agreement under which Bristol Myers Squibb will acquire Turning Point Therapeutics for $76.00 per share. The transaction was unanimously approved by both the Bristol Myers Squibb and Turning Point Therapeutics Board of Directors and is anticipated to close during the third quarter of 2022.
  • In August 2022, American drug maker Pfizer announced a deal to acquire Global Blood Therapeutics, makers of a recently approved treatment for sickle cell disease, for US$ 5.4 billion.
  • In June 2022, Novartis AG's medicine lapatinib helped reduce brain tumors in patients with a type of lung cancer in a mid-stage study. New data has shown that the drug benefited a subset of patients who had brain metastases in which tumors develop away from the initial site of cancer.

Report Scope

Report Attribute Details
Growth Rate CAGR of 7.2% from 2023 to 2033
Market Value in 2023 US$ 3,114.2 million
Market Value in 2033 US$ 6,228.2 million
Base Year for Estimation 2022
Historical Data 2018 to 2022
Forecast Period 2023 to 2033
Quantitative Units Revenue in US$ million and CAGR from 2023 to 2033
Report Coverage Revenue Forecast, Company Ranking, Competitive Landscape, Growth Factors, Trends, and Pricing Analysis
Segments Covered
  • Product
  • End User
  • Region
Regions Covered
  • North America
  • Latin America
  • Europe
  • Asia Pacific
  • Middle East and Africa
Key Countries Profiled
  • The United States
  • Canada
  • Brazil
  • Mexico
  • Germany
  • The United Kingdom
  • France
  • Spain
  • Italy
  • China
  • Japan
  • South Korea
  • GCC Countries
  • South Africa
  • Israel
Key Companies Profiled
  • Genentech USA
  • Bristol Myers Squibb
  • Hoffmann- La Roche
  • AstraZeneca Plc.
  • Pfizer Inc.
  • Novartis AG
  • Antisense Pharma
  • Merck & Co
  • MacLeod’s Pharmaceutical Limited
  • Mankind Pharma
  • Siemens Healthineers AG
  • Dr. Reddy’s Laboratories Ltd.

Key Segments Covered in the Brain Tumor Treatment Industry Analysis

By Product:

  • Temozolomide
  • Carmustine
  • Cisplatin
  • Bevacizumab
  • Geftinib
  • Erlotinib

By End User:

  • Hospital Pharmacies
  • Ambulatory Surgical Centers
  • Individual Pharmacies

By Region:

  • North America
  • Latin America
  • Europe
  • Asia Pacific
  • Middle East & Africa

Frequently Asked Questions

What is the Market's Growth Potential?

The market is forecast to register a CAGR of 7.2% through 2033.

What is the Projected Market Size by 2033?

The market is valued to hit US$ 6,228.2 million by 2033.

What Historical Changes Did the Market Experience?

The global market advanced at a 4.7% CAGR from 2018 to 2022.

How Significant Is the Market?

The market is estimated to secure a valuation US$ 3,114.2 million in 2023.

What Is the Market Share of North America?

In 2023, North America may command a 34.2% market share.

What Is Europe's Market Share?

The projected global market share for Europe is 24.2%.

What Is the Market CAGR for China?

The China market to record a market CAGR of 8.8% through 2033.

Table of Content

1. Executive Summary

    1.1. Global Market Outlook

    1.2. Demand-side Trends

    1.3. Supply-side Trends

    1.4. Technology Roadmap Analysis

    1.5. Analysis and Recommendations

2. Market Overview

    2.1. Market Coverage / Taxonomy

    2.2. Market Definition / Scope / Limitations

3. Market Background

    3.1. Market Dynamics

        3.1.1. Drivers

        3.1.2. Restraints

        3.1.3. Opportunity

        3.1.4. Trends

    3.2. Scenario Forecast

        3.2.1. Demand in Optimistic Scenario

        3.2.2. Demand in Likely Scenario

        3.2.3. Demand in Conservative Scenario

    3.3. Opportunity Map Analysis

    3.4. Investment Feasibility Matrix

    3.5. PESTLE and Porter’s Analysis

    3.6. Regulatory Landscape

        3.6.1. By Key Regions

        3.6.2. By Key Countries

    3.7. Regional Parent Market Outlook

4. Global Market Analysis 2018 to 2022 and Forecast, 2023 to 2033

    4.1. Historical Market Size Value (US$ Million) Analysis, 2018 to 2022

    4.2. Current and Future Market Size Value (US$ Million) Projections, 2023 to 2033

        4.2.1. Y-o-Y Growth Trend Analysis

        4.2.2. Absolute $ Opportunity Analysis

5. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Product

    5.1. Introduction / Key Findings

    5.2. Historical Market Size Value (US$ Million) Analysis By Product, 2018 to 2022

    5.3. Current and Future Market Size Value (US$ Million) Analysis and Forecast By Product, 2023 to 2033

        5.3.1. Temozolomide

        5.3.2. Carmustine

        5.3.3. Cisplatin

        5.3.4. Bevacizumab

        5.3.5. Geftinib

        5.3.6. Erlotinib

    5.4. Y-o-Y Growth Trend Analysis By Product, 2018 to 2022

    5.5. Absolute $ Opportunity Analysis By Product, 2023 to 2033

6. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By End User

    6.1. Introduction / Key Findings

    6.2. Historical Market Size Value (US$ Million) Analysis By End User, 2018 to 2022

    6.3. Current and Future Market Size Value (US$ Million) Analysis and Forecast By End User, 2023 to 2033

        6.3.1. Hospital Pharmacies

        6.3.2. Ambulatory Surgical Centers

        6.3.3. Individual Pharmacies

    6.4. Y-o-Y Growth Trend Analysis By End User, 2018 to 2022

    6.5. Absolute $ Opportunity Analysis By End User, 2023 to 2033

7. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Region

    7.1. Introduction

    7.2. Historical Market Size Value (US$ Million) Analysis By Region, 2018 to 2022

    7.3. Current Market Size Value (US$ Million) Analysis and Forecast By Region, 2023 to 2033

        7.3.1. North America

        7.3.2. Latin America

        7.3.3. Western Europe

        7.3.4. Eastern Europe

        7.3.5. South Asia and Pacific

        7.3.6. East Asia

        7.3.7. Middle East and Africa

    7.4. Market Attractiveness Analysis By Region

8. North America Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country

    8.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022

    8.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033

        8.2.1. By Country

            8.2.1.1. USA

            8.2.1.2. Canada

        8.2.2. By Product

        8.2.3. By End User

    8.3. Market Attractiveness Analysis

        8.3.1. By Country

        8.3.2. By Product

        8.3.3. By End User

    8.4. Key Takeaways

9. Latin America Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country

    9.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022

    9.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033

        9.2.1. By Country

            9.2.1.1. Brazil

            9.2.1.2. Mexico

            9.2.1.3. Rest of Latin America

        9.2.2. By Product

        9.2.3. By End User

    9.3. Market Attractiveness Analysis

        9.3.1. By Country

        9.3.2. By Product

        9.3.3. By End User

    9.4. Key Takeaways

10. Western Europe Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country

    10.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022

    10.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033

        10.2.1. By Country

            10.2.1.1. Germany

            10.2.1.2. UK

            10.2.1.3. France

            10.2.1.4. Spain

            10.2.1.5. Italy

            10.2.1.6. Rest of Western Europe

        10.2.2. By Product

        10.2.3. By End User

    10.3. Market Attractiveness Analysis

        10.3.1. By Country

        10.3.2. By Product

        10.3.3. By End User

    10.4. Key Takeaways

11. Eastern Europe Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country

    11.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022

    11.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033

        11.2.1. By Country

            11.2.1.1. Poland

            11.2.1.2. Russia

            11.2.1.3. Czech Republic

            11.2.1.4. Romania

            11.2.1.5. Rest of Eastern Europe

        11.2.2. By Product

        11.2.3. By End User

    11.3. Market Attractiveness Analysis

        11.3.1. By Country

        11.3.2. By Product

        11.3.3. By End User

    11.4. Key Takeaways

12. South Asia and Pacific Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country

    12.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022

    12.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033

        12.2.1. By Country

            12.2.1.1. India

            12.2.1.2. Bangladesh

            12.2.1.3. Australia

            12.2.1.4. New Zealand

            12.2.1.5. Rest of South Asia and Pacific

        12.2.2. By Product

        12.2.3. By End User

    12.3. Market Attractiveness Analysis

        12.3.1. By Country

        12.3.2. By Product

        12.3.3. By End User

    12.4. Key Takeaways

13. East Asia Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country

    13.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022

    13.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033

        13.2.1. By Country

            13.2.1.1. China

            13.2.1.2. Japan

            13.2.1.3. South Korea

        13.2.2. By Product

        13.2.3. By End User

    13.3. Market Attractiveness Analysis

        13.3.1. By Country

        13.3.2. By Product

        13.3.3. By End User

    13.4. Key Takeaways

14. Middle East and Africa Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country

    14.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022

    14.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033

        14.2.1. By Country

            14.2.1.1. GCC Countries

            14.2.1.2. South Africa

            14.2.1.3. Israel

            14.2.1.4. Rest of MEA

        14.2.2. By Product

        14.2.3. By End User

    14.3. Market Attractiveness Analysis

        14.3.1. By Country

        14.3.2. By Product

        14.3.3. By End User

    14.4. Key Takeaways

15. Key Countries Market Analysis

    15.1. USA

        15.1.1. Pricing Analysis

        15.1.2. Market Share Analysis, 2022

            15.1.2.1. By Product

            15.1.2.2. By End User

    15.2. Canada

        15.2.1. Pricing Analysis

        15.2.2. Market Share Analysis, 2022

            15.2.2.1. By Product

            15.2.2.2. By End User

    15.3. Brazil

        15.3.1. Pricing Analysis

        15.3.2. Market Share Analysis, 2022

            15.3.2.1. By Product

            15.3.2.2. By End User

    15.4. Mexico

        15.4.1. Pricing Analysis

        15.4.2. Market Share Analysis, 2022

            15.4.2.1. By Product

            15.4.2.2. By End User

    15.5. Germany

        15.5.1. Pricing Analysis

        15.5.2. Market Share Analysis, 2022

            15.5.2.1. By Product

            15.5.2.2. By End User

    15.6. UK

        15.6.1. Pricing Analysis

        15.6.2. Market Share Analysis, 2022

            15.6.2.1. By Product

            15.6.2.2. By End User

    15.7. France

        15.7.1. Pricing Analysis

        15.7.2. Market Share Analysis, 2022

            15.7.2.1. By Product

            15.7.2.2. By End User

    15.8. Spain

        15.8.1. Pricing Analysis

        15.8.2. Market Share Analysis, 2022

            15.8.2.1. By Product

            15.8.2.2. By End User

    15.9. Italy

        15.9.1. Pricing Analysis

        15.9.2. Market Share Analysis, 2022

            15.9.2.1. By Product

            15.9.2.2. By End User

    15.10. Poland

        15.10.1. Pricing Analysis

        15.10.2. Market Share Analysis, 2022

            15.10.2.1. By Product

            15.10.2.2. By End User

    15.11. Russia

        15.11.1. Pricing Analysis

        15.11.2. Market Share Analysis, 2022

            15.11.2.1. By Product

            15.11.2.2. By End User

    15.12. Czech Republic

        15.12.1. Pricing Analysis

        15.12.2. Market Share Analysis, 2022

            15.12.2.1. By Product

            15.12.2.2. By End User

    15.13. Romania

        15.13.1. Pricing Analysis

        15.13.2. Market Share Analysis, 2022

            15.13.2.1. By Product

            15.13.2.2. By End User

    15.14. India

        15.14.1. Pricing Analysis

        15.14.2. Market Share Analysis, 2022

            15.14.2.1. By Product

            15.14.2.2. By End User

    15.15. Bangladesh

        15.15.1. Pricing Analysis

        15.15.2. Market Share Analysis, 2022

            15.15.2.1. By Product

            15.15.2.2. By End User

    15.16. Australia

        15.16.1. Pricing Analysis

        15.16.2. Market Share Analysis, 2022

            15.16.2.1. By Product

            15.16.2.2. By End User

    15.17. New Zealand

        15.17.1. Pricing Analysis

        15.17.2. Market Share Analysis, 2022

            15.17.2.1. By Product

            15.17.2.2. By End User

    15.18. China

        15.18.1. Pricing Analysis

        15.18.2. Market Share Analysis, 2022

            15.18.2.1. By Product

            15.18.2.2. By End User

    15.19. Japan

        15.19.1. Pricing Analysis

        15.19.2. Market Share Analysis, 2022

            15.19.2.1. By Product

            15.19.2.2. By End User

    15.20. South Korea

        15.20.1. Pricing Analysis

        15.20.2. Market Share Analysis, 2022

            15.20.2.1. By Product

            15.20.2.2. By End User

    15.21. GCC Countries

        15.21.1. Pricing Analysis

        15.21.2. Market Share Analysis, 2022

            15.21.2.1. By Product

            15.21.2.2. By End User

    15.22. South Africa

        15.22.1. Pricing Analysis

        15.22.2. Market Share Analysis, 2022

            15.22.2.1. By Product

            15.22.2.2. By End User

    15.23. Israel

        15.23.1. Pricing Analysis

        15.23.2. Market Share Analysis, 2022

            15.23.2.1. By Product

            15.23.2.2. By End User

16. Market Structure Analysis

    16.1. Competition Dashboard

    16.2. Competition Benchmarking

    16.3. Market Share Analysis of Top Players

        16.3.1. By Regional

        16.3.2. By Product

        16.3.3. By End User

17. Competition Analysis

    17.1. Competition Deep Dive

        17.1.1. Genentech USA

            17.1.1.1. Overview

            17.1.1.2. Product Portfolio

            17.1.1.3. Profitability by Market Segments

            17.1.1.4. Sales Footprint

            17.1.1.5. Strategy Overview

                17.1.1.5.1. Marketing Strategy

        17.1.2. Bristol Myers Squibb

            17.1.2.1. Overview

            17.1.2.2. Product Portfolio

            17.1.2.3. Profitability by Market Segments

            17.1.2.4. Sales Footprint

            17.1.2.5. Strategy Overview

                17.1.2.5.1. Marketing Strategy

        17.1.3. Hoffmann- La Roche

            17.1.3.1. Overview

            17.1.3.2. Product Portfolio

            17.1.3.3. Profitability by Market Segments

            17.1.3.4. Sales Footprint

            17.1.3.5. Strategy Overview

                17.1.3.5.1. Marketing Strategy

        17.1.4. AstraZeneca Plc.

            17.1.4.1. Overview

            17.1.4.2. Product Portfolio

            17.1.4.3. Profitability by Market Segments

            17.1.4.4. Sales Footprint

            17.1.4.5. Strategy Overview

                17.1.4.5.1. Marketing Strategy

        17.1.5. Pfizer Inc.

            17.1.5.1. Overview

            17.1.5.2. Product Portfolio

            17.1.5.3. Profitability by Market Segments

            17.1.5.4. Sales Footprint

            17.1.5.5. Strategy Overview

                17.1.5.5.1. Marketing Strategy

        17.1.6. Novartis AG

            17.1.6.1. Overview

            17.1.6.2. Product Portfolio

            17.1.6.3. Profitability by Market Segments

            17.1.6.4. Sales Footprint

            17.1.6.5. Strategy Overview

                17.1.6.5.1. Marketing Strategy

        17.1.7. Antisense Pharma

            17.1.7.1. Overview

            17.1.7.2. Product Portfolio

            17.1.7.3. Profitability by Market Segments

            17.1.7.4. Sales Footprint

            17.1.7.5. Strategy Overview

                17.1.7.5.1. Marketing Strategy

        17.1.8. Merck & Co

            17.1.8.1. Overview

            17.1.8.2. Product Portfolio

            17.1.8.3. Profitability by Market Segments

            17.1.8.4. Sales Footprint

            17.1.8.5. Strategy Overview

                17.1.8.5.1. Marketing Strategy

        17.1.9. MacLeod’s Pharmaceutical Limited

            17.1.9.1. Overview

            17.1.9.2. Product Portfolio

            17.1.9.3. Profitability by Market Segments

            17.1.9.4. Sales Footprint

            17.1.9.5. Strategy Overview

                17.1.9.5.1. Marketing Strategy

        17.1.10. Mankind Pharma

            17.1.10.1. Overview

            17.1.10.2. Product Portfolio

            17.1.10.3. Profitability by Market Segments

            17.1.10.4. Sales Footprint

            17.1.10.5. Strategy Overview

                17.1.10.5.1. Marketing Strategy

        17.1.11. Siemens Healthineers AG

            17.1.11.1. Overview

            17.1.11.2. Product Portfolio

            17.1.11.3. Profitability by Market Segments

            17.1.11.4. Sales Footprint

            17.1.11.5. Strategy Overview

                17.1.11.5.1. Marketing Strategy

        17.1.12. Dr. Reddy’s Laboratories Ltd.

            17.1.12.1. Overview

            17.1.12.2. Product Portfolio

            17.1.12.3. Profitability by Market Segments

            17.1.12.4. Sales Footprint

            17.1.12.5. Strategy Overview

                17.1.12.5.1. Marketing Strategy

18. Assumptions & Acronyms Used

19. Research Methodology

Recommendations

Healthcare

Brain Imaging And Neuroimaging Market

Published : July 2023

Healthcare

Brain Monitoring Systems Market

Published : January 2023

Explore Healthcare Insights

View Reports

Brain Tumor Treatment Market